Belite Bio, Inc
BLTE
$155.54
$3.572.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 12/31/2024 | 12/31/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | 47.38% | 47.38% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 26.30% | 26.30% | -- |
| Operating Income | -- | -- | -26.30% | -26.30% | -- |
| Income Before Tax | -- | -- | -14.28% | -14.28% | -- |
| Income Tax Expenses | -- | -- | -33.33% | -33.33% | -- |
| Earnings from Continuing Operations | -- | -- | -14.26% | -14.26% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -14.26% | -14.26% | -- |
| EBIT | -- | -- | -26.30% | -26.30% | -- |
| EBITDA | -- | -- | -26.15% | -26.13% | -- |
| EPS Basic | -- | -- | 4.70% | 4.71% | -- |
| Normalized Basic EPS | -- | -- | -14.58% | -144.65% | -- |
| EPS Diluted | -- | -- | 4.70% | 4.71% | -- |
| Normalized Diluted EPS | -- | -- | -14.58% | -144.65% | -- |
| Average Basic Shares Outstanding | -- | -- | 19.32% | 19.32% | -- |
| Average Diluted Shares Outstanding | -- | -- | 19.32% | 19.32% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |